Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 67

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 67
---
,900 | ​ | ​         | ​ | ​ | ​ | 4,688,165 | ​ |         ​ |   |   |
| ​                                                        | ​ | ​ | 2022 | ​ |    ​ | ​ | ​ | ​ |   435,352 | ​ |           ​ | ​ | ​ | ​ |           — | ​ |      ​ | ​ | ​ | ​ |          3,538,605 | ​ |         ​ | ​ | ​ | ​ |                                 235,000 | ​ |       ​ | ​ | ​ | ​ |                   38,397 | ​ | ​         | ​ | ​ | ​ | 4,247,354 | ​ |         ​ |   |   |

(1) Amounts represent discretionary portion of annual performance-based bonuses awarded for the year indicated. For a description of the Company’s annual performance-based bonus program for 2024, see “Compensation Discussion and Analysis — Element of Our 2024 Executive Compensation Program — Annual Cash Performance Bonus” in this Proxy Statement. (2) This column reflects the aggregate grant date fair value of all time-vesting and performance-vesting option awards granted during the indicated year measured pursuant to Financial Accounting Standard Board Accounting Standards Codification Topic 718, the basis for computing stock-based compensation in our audited consolidated financial statements, excluding the effect of estimated forfeitures. This calculation assumes that the NEO will perform the requisite service for the award to vest in full as required by SEC rules. The performance-vesting options granted to Dr. Seehra in 2024 are eligible to vest contingent upon the achievement of two rigorous development goals, as further described under “Compensation Discussion and Analysis — Elements of Our 2024 Executive Compensation Program — Equity Compensation” in this Proxy Statement. As such, the grant date fair value of such awards is based on the probable outcome of the performance conditions as of the grant date. The maximum potential value of such awards (assuming the highest level of performance achievement) is $4,875,900. The assumptions we used in valuing options are described in the notes to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. These amounts do not reflect the actual economic value that will be realized by the NEO upon vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. (3) This column reflects the